Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000022261 | SCV000800643 | uncertain significance | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2017-12-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000022261 | SCV002232801 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2023-10-28 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 336 of the GALT protein (p.Met336Leu). This variant is present in population databases (rs111033810, gnomAD 0.004%). This missense change has been observed in individual(s) with galactosemia (PMID: 11397328, 17876724). ClinVar contains an entry for this variant (Variation ID: 25315). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALT protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000022261 | SCV004198508 | likely pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2024-02-24 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003480034 | SCV004226604 | likely pathogenic | not provided | 2022-12-21 | criteria provided, single submitter | clinical testing | PP3, PP4, PM2, PM3, PS4_moderate |